View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
October 7, 2009

Pacific Biosciences Receives Grant From NIH

Funding will support development of company’s SMRT biology applications

By CBR Staff Writer

Pacific Biosciences has received grants totaling more than $1.9m from the National Institutes of Health (NIH), as part of the American Recovery & Reinvestment Act of 2009 Research and Research Infrastructure Grand Opportunities grants program.

Reportedly, the grants received by Pacific Biosciences through the National Human Genome Research Institute (NHGRI) of the NIH include $1,190,022 divided over two years to support the development of a direct DNA methylation detection method.

DNA methylation is a chemical modification to DNA that causes changes in gene expression and regulation. DNA methylation and associated epigenetic factors are increasingly being recognised for their importance in the biology of development and disease processes such as cancer.

According to the NHGRI, the new awards will stimulate research in studies ranging from those aimed at understanding the function of the human genome to those intended to lead to improvements in the prevention, diagnosis and treatment of human illness.

Content from our partners
Rethinking cloud: challenging assumptions, learning lessons
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business

The company has also received an additional $714,406 in funding toward its existing NIH grant to support the continued development of its single molecule real time (SMRT) DNA sequencing technology. The funds will be used to support further performance enhancements and additional scientific publications describing the SMRT technology.

Steve Turner, chief technology officer for Pacific Biosciences, said: “Our SMRT sequencing approach will unify the formerly separate applications of DNA sequencing and methylation sequencing. The potential to visualise methylation status and other epigenomic markers as a by-product of ordinary DNA sequencing, with no change in sample preparation or run conditions, will save researchers time and cost while also providing added depth to the information they can obtain from sequencing projects.”

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.